Loading
A phase 2/3 trial of Disitamab vedotin and Cadonilimab in gastric & gastro-oesophageal junction cancer, run by RemeGen Co., Ltd., now recruiting.
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy is a phase 2/3 interventional study registered as NCT06221748 by RemeGen Co., Ltd., with 90 participants planned, started 2024-02-22 and due to reach its primary completion in 2026-12. Interventions recorded: Disitamab Vedotin Injection, Cadonilimab Injection and Paclitaxel Injection.
Shares RemeGen, Disitamab vedotin, HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Gastric & gastro-oesophageal junction cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Gastric & gastro-oesophageal junction cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors and the tag pipeline.